Start-Up Spotlight: Fractyl Attacks Insulin Resistance At Its Roots
Executive Summary
The company is developing a novel duodenal mucosal resurfacing technology designed to reverse the metabolic process that causes insulin resistance in people with type 2 diabetes.
You may also be interested in...
Fractyl Adds $100M Investment To Address Root Causes Of Type 2 Diabetes
The series F financing will allow the company to expand clinical research supporting its unique duodenal mucosal resurfacing approach to treating metabolic disease at its source.
Abbott Adds New Surgical Tissue Valves
The US FDA approved Abbott’s new Epic Plus stented tissue mitral valve and Epic Plus Supra stented tissue aortic valve.
GE Healthcare Expands Into Intraoperative Ultrasound By Acquiring BK Medical For $1.45Bn
BK Medical’s intraoperative imaging and surgical navigation technologies will help GE Healthcare’s ultrasound business expand outside diagnostic imaging into surgical and therapeutic interventions.